Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas
Status:
Withdrawn
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
This phase 1, multicenter, open-label study is designed to find the RP2D of volasertib, a
PLK1 inhibitor, and belinostat, an HDAC inhibitor, when given in combination to patients with
relapsed or refractory B-cell or T-cell lymphoma. A standard 3+3 dose-escalation design will
be employed with study enrollment beginning at dose level 1.
Phase:
Phase 1
Details
Lead Sponsor:
Yale University
Collaborators:
Massey Cancer Center Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins